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Abstract
Background: Molecular characterization of breast and other cancers by gene expression profiling
has corroborated existing classifications and revealed novel subtypes. Most profiling studies are
based on fresh frozen (FF) tumor material which is available only for a limited number of samples
while thousands of tumor samples exist as formalin-fixed, paraffin-embedded (FFPE) blocks.
Unfortunately, RNA derived of FFPE material is fragmented and chemically modified impairing
expression measurements by standard procedures. Robust protocols for isolation of RNA from
FFPE material suitable for stable and reproducible measurement of gene expression (e.g. by
quantitative reverse transcriptase PCR, QPCR) remain a major challenge.
Results: We present a simple procedure for RNA isolation from FFPE material of diagnostic
samples. The RNA is suitable for expression measurement by QPCR when used in combination
with an optimized cDNA synthesis protocol and TaqMan assays specific for short amplicons. The
FFPE derived RNA was compared to intact RNA isolated from the same tumors. Preliminary scores
were computed from genes related to the ER response, HER2 signaling and proliferation.
Correlation coefficients between intact and partially fragmented RNA from FFPE material were
0.83 to 0.97.
Conclusion: We developed a simple and robust method for isolating RNA from FFPE material.
The RNA can be used for gene expression profiling. Expression measurements from several genes
can be combined to robust scores representing the hormonal or the proliferation status of the
tumor.
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Breast cancer has been widely studied in the past and
molecular characterization has increased the understand-
ing of biological pathways that are altered during neoplas-
tic transformation of cells [1-4]. However, the findings
based on molecular profiling have not yet altered diagno-
sis, and decisions about treatment still rely mostly on his-
topathological and immunohistochemical techniques
which are at best semi-quantitative [5,6]. Currently, many
patients with primary, non-metastatic breast cancer with
positive estrogen receptor (ER) status undergo several
cycles of chemotherapy, although a substantial propor-
tion of them does not benefit from it. Presently, no con-
ventional parameters exist for many patients which allow
to identify individuals who will benefit from chemother-
apy. Personalized diagnosis on the basis of highly specific
molecular analyses has the potential to improve the situ-
ation of many patients by optimizing medication, and at
the same time, sparing others from unnecessary treatment
regimens.
DNA chip studies are based on measuring gene expression
for many genes in parallel [1,4,7,8]. Most protocols for
gene expression analysis on the basis of DNA chips are
sensitive to RNA degradation and RNA must be isolated
from freshly prepared or FF tumor material. As a conse-
quence, material is fairly limited and often originates
from convenience samples of heterogeneous patients.
Many of these studies including meta-analyses have
revealed genes and biological functions of their products
which are relevant for classification and prognosis [9,10].
However, many samples were derived from patients who
did not participate in clinical studies and their treatment
regimens were not standardized. Therefore, follow up
data must still be interpreted with caution.
Obviously, procedures based on formalin-fixed, paraffin-
embedded (FFPE) material would greatly facilitate and
speed up research in this area as large amounts of highly
valuable material and clinical data have already been col-
lected. In many cases, FFPE blocks are still available and
they could be used for a molecular analysis. Especially
material from clinical trials would allow investigating dis-
tinct clinical questions with existing material rather than
material from newly designed studies.
Many efforts are currently made to individualize diagnosis
of breast cancer by including molecular parameters into
diagnosis. Fresh frozen material would obviously be ideal
for a molecular analysis by gene expression measurements
but it may be difficult to implement novel procedures
which complicate current workflows of daily routine. Pro-
cedures based on FFPE material would be more feasible as
they do not interfere with current protocols and they do
not affect routine diagnosis as material for molecular
analysis could be collected after standard diagnosis has
been terminated. Only relatively few molecular
approaches have been described which are based on FFPE
material. For example, Paik and co-workers have estab-
lished a recurrence score (RS, Oncotype DX), it allows to
quantify the likelihood of distant recurrence and to pre-
dict the magnitude of chemotherapy benefit [11,12].
It is generally accepted that molecular profiles which
reflect primarily biological characteristics of tumor cells,
may complement clinical and histopathological diagno-
sis, resulting in a more detailed characterization of indi-
vidual tumors, a pre-requisite for better treatment
decisions. In this study we present the development of a
novel procedure for RNA isolation from FFPE material
and an optimized workflow for expression measurements
by QPCR.
Methods
Human breast cancer samples
Human breast cancer specimens were divided into two
aliquots, one of which was processed for histological diag-
nosis by fixation with formalin and embedding in paraf-
fin. FFPE material was obtained from the Institute of
Pathology (University of Bern) and the Pathology Längg-
asse, Bern. Tissue (3–5 mm thick slices of tumor) was
fixed over night in buffered formalin and processed for
paraffin embedding in a Tissue Processing Center TPC 15
(Medite Medizintechnik, Germany). The second aliquot
was frozen on dry ice and stored at -80°C. Fresh frozen
material was obtained from the Tumorbank Bern. Both,
FF and FFPE samples were checked by hematoxylin and
eosin staining and only samples with more than 50%
tumor cells were used for this study. An informed consent
to use the material for research was obtained from all the
patients.
RNA Extraction
Intact RNA was isolated from four 25 μm thick kryo-sec-
tions of approximately 0.5 cm2. The tissue was homoge-
nized in 420 μl lysis buffer (4 M guanidinium
thiocyanate, 30 mM Tris pH 8.0, 1% Triton-X-100), 8.0,1
using a TissueLyser (Mixer Mill, Retsch GmbH, Haan, Ger-
many) at 15 Hz for 3 min. Total RNA was bound to silica-
based columns (Epoch Biolabs, Huston Texas), treated
with DNase I (30 Kunitz units for 20 min. at room tem-
perature; Qiagen, Hilden, Germany), washed once with
lysis buffer (containing 30% ethanol) and once with 20
mM NaCl (containing 20% ethanol) and eluted in 50 μl
10 mM Tris pH 7.4, 0.1 mM EDTA and stored at -20°C.
RNA quantity was measured on an ND-1000 spectropho-
tometer (NanoDrop Technologies, Wilmington, DE) and
quality assessed by capillary electrophoresis with an Agi-
lent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa
Clara, CA) using Agilent RNA 6000 Series Nano kits.Page 2 of 15
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according to the RNeasy FFPE protocol of Qiagen (Fig. 1,
lanes B), the ncLysis protocol of Applied Biosystems
(lanes C) and the protocol developed in our laboratory
(lanes D). Paraffin sections were de-paraffinized with
xylene, washed with ethanol and dried in a speed vac. For
our own protocol, 200 μl lysis buffer (4 M guanidinium
thiocyanate, 30 mM Tris, pH 8.0, 1% Triton-X-100) was
added to the dried sections and immediately homoge-
nized in a Mixer Mill at 20 Hz for 4 min. Proteinase K
(Roche Diagnostics, Mannheim, Germany) was added (1
mg/ml final concentration) and tissue was digested for 1
hour at 55°C. One milliliter dilution buffer (30 mM Tris,
pH 8.0, 1% Triton-X-100) was added to each lysate and
digestion continued for 1 hr after adding fresh proteinase
K (final concentration 1 mg/ml). RNA was de-modified by
adding 318 μl of de-modification solution (5 M NH4Cl)
and incubating at 94°C for 20 min or as described in the
text. RNA was bound to silica-based columns and digested
with DNase I as described for fresh-frozen tissue samples.
The reproducibility of our own procedure was tested by
isolating several independent RNAs from consecutive sec-
tions of the same tissue block. About 10 μg of total RNA
could be isolated from 5 to 10 FFPE sections (0.5–1 cm2/
section). RNA was isolated from closely matched sections
using the RNeasy FFPE kit (Qiagen) or the ncLysis system
(Applied Biosystems) according to the protocols included
with the kits. In both cases, the RNA was purified on silica-
based columns. 22 samples were available. In 14 cases suf-
ficient RNA was obtained from all 4 parallel isolations. In
2 cases of FF material (samples 4 and 11) and in 6 cases of
FFPE material (samples 1, 5, 7, 9, 12 and 21) less than 1.5
μg RNA could be isolated with the ncLysis protocol. These
samples were excluded from further analysis.
cDNA synthesis and QPCR
Aliquots of 100 to 500 ng of total RNA were reverse tran-
scribed using MultiScribe™ MuLV reverse transcriptase
(High-Capacity cDNA Archive Kit; Applied Biosystems,
Foster City, CA, USA) and random or gene-specific prim-
ers. Reverse primers were kindly provided by Applied Bio-
systems, they were used at 1 μM each, cDNAs were made
in the presence of 3, 10 or 22 reverse primers as 3-plex, 10-
plex or 22-plex, respectively. Regular Assays on Demand
(Applied Biosystems) were used for QPCR (Table 1).
Manually designed assays coding for short, medium-size
and long amplicons of the insulin growth factor-binding
protein 5 (IGBP5) were selected with Primer Express (Ver-
sion 3, Applied Biosystems). Forward primer and probe
were kept constant for all assays while reverse primers
were selected such that amplicons of different sizes were
generated [13]. QPCR reactions were carried out in tripli-
cates in a final volume of 10 μl in 1× FAST Master mix
(Applied Biosystems) and cDNA corresponding to 4 ng
total RNA. QPCR was performed on an ABI 7500 FAST
instrument (2 min at 95°C, followed by 45 cycles of 95°C
for 3 sec and 60°C for 30 sec). The quality of the assays
and the absence of contaminating DNA were assessed
with water and RNA instead of cDNA, respectively (data
not shown). Three positive controls containing cDNA
derived of ZR-7-51 cells were included on each 96-well
plate. Cycle threshold values (Ct) were determined using
the SDS software of the 7500 FAST System (Version
1.3.1). Constant threshold values were set for each gene
throughout the study.
RNA isolation and characterizationFigure 1
RNA isolation and characterization. Total RNA was 
isolated from kryo-sections (lanes A) and from paraffin sec-
tions according to the RNeasy FFPE protocol of Qiagen 
(lanes B), the ncLysis protocol of Applied Biosystems (lanes 
C) or according to our own protocol (lanes D). Aliquots of 
each RNA were separated by capillary electrophoresis (Agi-
lent Bioanalyzer) on Nano chips along with RNA ladder (L; 
Ambion). Shown are RNAs from two representative tumors 
(Tu#10 and #18).Page 3 of 15
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classification scores
All the measured cycle threshold (Ct) values represent
log2 expression levels. These values need to be normalized
such that they are comparable across samples and suitable
for generating scores. For a gene, a large Ct value corre-
sponds to a low expression level, so the first processing
step needed was to reverse the sense of this relationship by
letting
Ct' = max(cut_off - Ct, 0)
be the new value for each measured gene. The cut off value
was set empirically to 35.0 as any higher raw Ct value was
deemed unreliable. This cut off was fixed a priori and kept
constant throughout all the experiments reported here.
Then, the final value of each target gene was taken to be
ΔCt = max_val*(Ct' - R + cut_off)/(2*cut_off),
where R represents the reference value and was taken as
the mean of Ct' values of 5 selected reference genes
(GAPDH, GUSB, RPLP0, TFRC, UBB, see Results section
for details). The approach guarantees that all ΔCt values
are positive and upper bounded by max_val (set to 33 for
all the results reported here).
We used the scores associated with three of the gene
groups listed in Table 1: the ER, HER2 and Proliferation
group. While for the HER2 and Proliferation groups the
scores were taken as the average ΔCt value of the genes in
the group, for the ER group more weight was given to the
ESR1 gene:
ER_score = 0.55*ESR1 + 0.15*(BCL2 + CEGP1 + PGR)
where the gene symbols stand for the corresponding ΔCt
values.
Finally, for each tumor a Total score was computed as
Total_score = (Proliferation_score + HER2_score - 
ER_score + max_val)/3
The Total score, together with the group scores as com-
puted above, are used in all subsequent discussions.
Table 1: QPCR assays. QPCR assays (Assays on Demand) were from Applied Biosystems (Palo Alto, CA). Reverse primers from each 
assay were used for the synthesis of gene-specific cDNAs. They were provided separately by Applied Biosystems. Three assays 
(IGBP5_short, IGBP5_medium, IGBP5_long) were designed manually.
AoD Assay Acc_Nr AmpliconSize Module
Hs00608023_m1 BCL2 NM_000633 81 Estrogen
Hs00221277_m1 CEGP1 NM_020974 64 Estrogen
Hs00174860_m1 ESR1 NM_000125 62 Estrogen
Hs00172183_m1 PGR NM_000926 118 Estrogen
Hs00180450_m1 GRB7 NM_005310 70 Her2
Hs01001598_g1 HER2 NM_004448 55 Her2
Hs00952036_m1 CTSL2 NM_001333 72 Invasion
Hs00171829_m1 STMY3 NM_005940 66 Invasion
Hs01030097_m1 CCNB1 NM_031966 66 Proliferation
Hs01032443_m1 MKI67 NM_002417 66 Proliferation
Hs00231158_m1 MYBL2 NM_002466 81 Proliferation
Hs00269212_m1 STK15 NM_003600 85 Proliferation
Hs00153353_m1 SURV NM_001168 93 Proliferation
Hs99999903_m1 ACTB NM_001101 171 Reference
Hs00266705_g1 GAPDH NM_002046 74 Reference
Hs99999908_m1 GUSB NM_000181 81 Reference
Hs99999902_m1 RPLP0 NM_001002 105 Reference
Hs00174609_m1 TFRC NM_003234 79 Reference
Hs00430290_m1 UBB NM_018955 120 Reference
Hs01630490_s1 RPL7A BX641050 84 Reference
Hs00817975_g1 RPS11 NM_001015 168 Reference
Hs01922548_s1 RPS23 NM_001025 90 Reference
Hs00185390_m1 BAG1 NM_004323 58
Hs00154355_m1 CD68 NM_001251 68
Hs01383449_s1 GSTM1 AY532925 65
(own design) IGBP5_short NM_000599 60 Test
(own design) IGBP5_medium NM_000599 109 Test
(own design) IGBP5_long NM_000599 147 TestPage 4 of 15
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Isolation of RNA from FFPE material
Total RNA was isolated from FF human breast cancer spec-
imen which resulted in intact RNA in all samples (Fig. 1,
lanes A, shown are RNAs from two representative tumors
from a series of 14 tumors). RNA from FF tissue was used
as reference for partially fragmented RNA isolated from
FFPE material of the same tumors. RNA was assessed by
capillary electrophoresis. The size distribution of RNA iso-
lated according to our own protocol was in the range of
200 to 1000 nucleotides (Fig. 1, panel D) while the major-
ity of RNA fragments was in the range of 100 nucleotides
when RNA was isolated according to RNeasy FFPE (panel
B) or the ncLysis system (panel C). Gene expression was
measured by QPCR using 25 commercially available and
three own TaqMan assays [13] (Tab. 1). The cycle thresh-
old values (Ct values) were determined from RNAs iso-
lated according to one of the three protocols for FFPE
material and compared to Cts obtained with intact RNA of
the same tumors. Fig. 2 shows correlation coefficients
between intact RNA (A) and FFPE-derived RNAs isolated
according to the RNeasy FFPE protocol, (A vs B); the ncL-
ysis system (A vs C); or our own protocol (A vs D) for all
14 tumors using the expression levels of 5 genes (GAPDH,
GUSB, RPLP0, TFRC, UBB; see below). The cDNAs were
made in the presence of random (white boxes) or gene-
specific primers (gray boxes). Clearly, correlation coeffi-
cients between intact and partially fragmented RNA were
higher with gene-specific primers than random primers
and RNA isolated according to our own protocol resulted
in cDNA which performed better in QPCR than cDNA
made from RNA isolated according to RNeasy FFPE and
ncLysis protocols.
Parameters affecting the RNA quality and QPCR
Several parameters were systematically optimized to
improve the protocol for RNA isolation from FFPE-
derived sections. For example, QPCR made in the pres-
ence of primers specific for large amplicons (Fig. 3, dashed
line) is very sensitive to RNA fragmentation and modifica-
tion resulting in higher Ct values than primers specific for
medium-size amplicons (dotted line) or short amplicons
(non-interrupted line). In addition, the effect of de-mod-
ification of FFPE-derived RNA is apparent: the Ct deter-
mined from de-modified RNA is 3 or more units lower
than the Ct measured from the same RNA but without de-
modification. The effect was consistently observed with
several tumors and also when expression was measured
Comparison of RNAs isolated according to different protocolsFigure 2
Comparison of RNAs isolated according to different protocols. RNA was reverse transcribed in the presence of ran-
dom primers (white boxes) or gene-specific primers (hatched boxes). Gene expression was measured from an equivalent of 4 
ng of RNA by QPCR for five reference genes (GAPDH, GUSB, RPLP0, TFRC and UBB). Pearson correlations were computed 
between matched Cts for the five reference genes and each tumor RNA isolated from FF (A) and FFPE material. Shown are 
correlations between intact RNA and RNA isolated from FFPE material according to the RNeasy FFPE protocol (A versus B), 
intact RNA and RNA isolated from FFPE material according to the ncLysis system (A versus C) and intact RNA and RNA iso-
lated according to our own protocol (A versus D).Page 5 of 15
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shown). The optimum time of demodification was 20
min, longer times led to higher Ct values (not shown).
The different protocols of RNA isolation from FFPE mate-
rial were further compared by measuring expression levels
of reference genes in the 14 tumors and by comparing the
results to Cts generated from corresponding intact RNAs
(Fig. 4). Experimental variation was reduced by compar-
ing mean Ct values from 5 reference genes (GAPDH,
GUSB, RPLP0, TFRC, UBB) instead of their single values.
Mean Cts of the five reference genes were plotted for each
tumor and each protocol (panel A) and their distribution
summarized (panel B). As expected, the Ct values gener-
ated with intact RNA resulted in the lowest and most sta-
ble Cts (diamonds). RNA prepared from FFPE tissue
according to our own protocol (circles) resulted in higher
but fairly constant Ct values (compare diamonds and cir-
cles). RNA isolated according to the RNeasy FFPE protocol
(squares) and the ncLysis protocol (triangles) resulted in
Ct values that were not only much higher than with intact
RNA, they also exhibited large variations among different
isolates when compared to corresponding Cts based on
intact RNA. This result suggests a generally poorer and
more variable quality of RNA isolated according to the
two commercial protocols than our own protocol, leading
to relatively large variations of Cts for the 5 reference
genes among the different tumors. The Ct values gener-
ated from RNA isolated according to our own protocol
were on average 2.9 units higher than Cts from intact
RNA. RNA isolated according to RNeasy FFPE and ncLysis
were 7.6 and 5.8 units higher than Cts from intact RNA of
the same tumors, respectively (Fig. 4B). Standard devia-
tions of Cts for the 14 tumors were 0.45 for intact RNA,
De-modification of RNA results in higher efficiency during subsequent QPCRFigure 3
De-modification of RNA results in higher efficiency during subsequent QPCR. RNA was isolated from FFPE material 
according to our own protocol and compared to intact RNA derived of FF tissue. RNA samples were reverse transcribed 
without previous de-modification (labeled "no") or after de-modification at room temperature (1), 94°C and pH 8.0 (2) or 
94°C and pH 5.0 (3). Each RNA was tested by QPCR using three amplicons for IGBP5. Primers used code for short (60 bp, ), 
medium-size (109 bp, ) or long amplicons (147 bp, ). Shown are raw Ct values from intact RNAs from FF material and 
from RNAs derived of FFPE material of the same tumors. The benefit of de-modification is visualized as delta Ct values. They 
are indicated for short and long amplicons (dotted lines).Page 6 of 15
(page number not for citation purposes)
BMC Medical Genomics 2008, 1:9 http://www.biomedcentral.com/1755-8794/1/9and 4.21, 2.69 and 1.01 for FFPE-derived RNA isolated
according to the RNeasy FFPE, ncLysis and our own pro-
tocol, respectively.
An important aspect when working with RNA from FFPE
material relates to the reproducibility of the RNA isolation
procedure. This was directly tested for our own protocol
by isolating independent samples of RNA from closely
matched FFPE sections of the same tissue block and meas-
uring gene expression by QPCR from both RNAs (Fig. 5A
and 5B showing two representative examples). RNAs were
also isolated from two independent tumors from the
same patient, resulting in a third panel of data sets (C).
Data points are shown as polygonal diagrams of raw Cts
for each gene measured. Horizontal, parallel lines indicate
closely similar expression, crossing lines indicate discrep-
ancies between two measurements in matched samples.
The Pearson correlation of raw Cts between matched sam-
ples was 0.99 for replicates shown in panels A and B and
0.74 for results shown in panel C.
Normalization
Results generated in the presence of partially fragmented
RNA cannot be directly aligned with results produced
from intact RNA and a suitable normalization is required
to eliminate or reduce the effects of fragmentation and
residual modification in RNA from FFPE material. Nine
putative reference genes were selected from the literature
[14] and from microarray results [15]. Expression was
measured from intact and FFPE-derived RNA and raw Cts
from all the 14 tumors are plotted for each putative refer-
ence gene (Fig. 6). Analyses based on intact RNAs revealed
that 8 of the 9 tested genes performed similarly well
(panel A). RPS23 which was hardly measurable (mean Ct
in intact RNA > 37) was characterized by a large variation
between the different tumors. A slightly higher variation
was observed when expression levels were compared for
FFPE-derived RNAs (panel B): GAPDH, GUSB, RPLP0,
TFRC, RPL7A and UBB showed a similar performance and
small variations between the 14 tumors as was seen with
intact RNA. In contrast, the Ct values with RNA from FFPE
material revealed larger variations for ACTB and RPS11
and therefore, the two genes were excluded as reference
genes. The ACTB and RPS11 amplicons are larger than
amplicons for the other reference genes and also for the
test genes (Tab. 1, see also Fig. 3). Five genes were used as
reference genes: GAPDH, GUSB, RPLP0, TFRC and UBB.
For comparison, raw Ct values are shown for 4 genes
related to the ER response (BCL2, CEPG1, ESR1, PGR)
(Fig. 6, left). As expected, a high variation was observed
for these genes between the 14 tumors. Protocols B and C
did not yield enough usable data, precluding the data
from further analysis. For example, protocol B did not
have data for all the reference genes and for protocol C
Comparison of RNA isolation methodsFigure 4
Comparison of RNA isolation methods. Shown are the means of raw Cts of five reference genes (GAPDH, GUSB, RPLP0, 
TFRC, UBB) for intact RNA (, FF) and for RNA isolated from matched FFPE material according to the protocols of Qiagen 
(, Q), Applied Biosystems (, AB) and our own ( , own). Individual mean Cts of the 14 tumors and summarized box plots of 
Cts are shown in panel A and panel B, respectively. Tumors are aligned according to increasing Ct in FFPE-derived RNA (Qia-
gen protocol).Page 7 of 15
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BCL2, PGR of the ER group).
RNAs isolated from FFPE material according to our own
protocol were also compared to RNA derived of kryo-pre-
served material of the same tumors in a different way. The
arithmetic mean of the five reference genes (GAPDH,
GUSB, RPLP0, TFRC and UBB) was used for normalizing
expression values of all the genes in each RNA. Normal-
ized expression values were compared between intact and
FFPE-derived RNA for each gene and each tumor [see
Additional File 1]. Good conservation of inter-tumor dif-
ferences were observed between kryo-preserved and FFPE
samples for most genes.
Module scores
Normalized expression values were also used to compute
scores representing ER-related genes (ESR1, PGR, BCL2,
CEPG1), HER2-related genes (HER2 and GRB7), genes
related to proliferation (STK15/AURKA, CCNB1, MYBL2,
MKI67, BIRC5/SURV) and a Total score representing all
the genes of the three scores (for details see Methods). The
computation of biologically meaningful scores with mul-
tiple genes instead of relying on just one has the scope to
reduce noise variation. Module scores and Total scores
were computed separately from normalized expression
values of intact RNAs (circles) and of RNAs isolated
according to our own protocol (triangles) and Total scores
are depicted separately for each tumor (Fig. 7). The figure
demonstrates that similar values are obtained for each
tumor irrespective of whether they are computed from
intact RNA or from RNA derived of FFPE material. This
suggests that scores can be computed with RNA from FF
samples as well as with RNA from FFPE samples. ER and
HER2 scores were visualized in scatter plots, where the ER
and HER2 scores were represented on the x- and y-axis,
respectively (Fig. 8A and 8B). It was apparent that the
three immunohistochemically ER-negative tumors have
low ER scores (#15, #18, #20) and the only immunohis-
tochemically HER2 positive tumor (#6) among the 14
tested tumors had a high HER2 score and an intermediate
ER score (see also Table 2). The remaining tumors were all
ER positive as assessed by immunohistochemistry (IHC)
and they had relatively high ER scores. ER-negative and
HER2-positive tumors all had high Proliferation scores
(visualized by the red color of the dots). A larger spectrum
of Proliferation scores (from blue to red) was found for ER
positive tumors. Similar distributions were found when
Reproducibility of RNA isolation from FFPE materialFigure 5
Reproducibility of RNA isolation from FFPE material. The RNAs were isolated from paraffin blocks according to our 
own protocol. BM33 and BM36 (panel A) are two separate RNAs isolated from tissue block "BM", D33 and D36 are RNAs iso-
lated from block "D" (panel B). For comparison, 45T and 56T originate from two distinct tumors isolated from one patient 
(panel C). Gene expression was measured by QPCR for 24 genes and raw Ct values are shown for each gene measured from 
the two matching RNAs.Page 8 of 15
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Stability of reference gene expression in RNA isolated from FF and FFPE materialFigure 6
Stability of reference gene expression in RNA isolated from FF and FFPE material. Raw Cts are shown for 9 puta-
tive reference genes (ACTB, GAPDH, GUSB, RPLP0, TFRC, RPL7A, RPS11, RPS23 and UBB). Results based on intact RNA 
derived of FF material (A) and based on RNA isolated according to our own protocol from FFPE material (B) are depicted for 
all the 14 tumors. The Ct values for 4 ER-related genes (BCL2, CEPG1, ESR1 and PGR) are shown for comparison (left).
BMC Medical Genomics 2008, 1:9 http://www.biomedcentral.com/1755-8794/1/9scores were computed from intact RNA (Fig. 8A) and
FFPE-derived RNA that was isolated according to our own
protocol (B). A different presentation of scores is shown
where ER, HER2, Proliferation and Total Scores are plot-
ted separately for each tumor [see Additional file 2]. The
scores determined from the 14 FF and FFPE-derived sam-
ples are in the same range and only few tumors were clas-
sified in a different order between intact and FFPE-derived
RNAs (leading to crossing lines).
The similarity between the results generated from intact
and partially fragmented RNA was also assessed by calcu-
lating Pearson correlation coefficients between the scores
of both RNAs. Correlation coefficients (and correspond-
ing p-values and 95% confidence intervals) were 0.966 (p
= 2.071*10-8, CI = 0.893; 0.989), 0.856 (p = 9.32*10-5,
CI = 0.597; 0.954) and 0.833 (p = 2.177*10-4, CI = 0.541;
0.946) for ER, HER2 and Proliferation scores, respectively.
The corresponding Spearman correlations were 0.938 (p <
2.2*10-16), 0.851 (p = 1.167*10-4) and 0.867 (p =
2.048*10-5), respectively.
Discussion
Methods and protocols for RNA isolation from formalin-
fixed tissues have been published since almost 20 years
[16-32].
RNA was quantified by dot blot hybridization [23], semi-
quantitative PCR [19] and more recently, by QPCR
[24,18,26,13,17,33,32] and other methods [28-30]. RNA
derived of FFPE material is not only partially hydrolyzed
but also chemically modified: formalin reacts with nucle-
otides leading to the formation of methylol groups in
nucleobases. These groups tend to further react and form
intra- and inter-molecular methylene bridges in RNA,
DNA [34,35,31] and protein [36]. As a result, reverse tran-
scription is impaired and threshold cycle values (Ct val-
ues) increase during subsequent QPCR.
The protocol for RNA isolation described here was com-
plemented by adding a separate demodification step
which involves incubation at elevated temperature in a
buffer containing ammonium chloride which favors the
reversion of methylol groups to amino groups in nucleo-
bases. It does not only improve the efficiency of down-
stream applications (mainly reverse transcription), it also
improves the recovery of RNA from FFPE sections. RNA
yield and quality can be further improved by extensive
digestion of FFPE material with protease in a buffer con-
taining guanidinium thiocyanate. Reverse transcription in
the presence of gene-specific primers prevents the initia-
tion of cDNA synthesis inside amplicons and therefore,
cDNA made in the presence of gene-specific primers is a
better template for QPCR than cDNA made from random
primers (Fig. 2). Several papers have demonstrated that
QPCR with primers coding for short amplicons are more
efficient than primers coding for long amplicons
[17,20,24,13,32].
Finally, normalization of raw data is used to eliminate or
at least reduce the effect of poorer quality of starting RNA.
Various approaches of normalization were proposed in
the literature [37,14,38,32]. They are based on calculating
relative expression values: expression levels of genes of
interest are expressed relative to the expression of one or a
panel of several suitable reference genes. An ideal refer-
Table 2: Clinical and molecular parameters of breast cancers. Clinical and molecular parameters are given for each breast cancer used 
in this study. Module scores for each tumor were calculated from the results based on intact RNA (FF material) and based on RNA 
isolated from FFPE material according to our own method. N.A., data not available.
Clinical classification Immunohistochemistry Module Score (FF/FFPE)
Tu# T N Grade ER PR ErbB2 ER HER2 Prolif. Histological type
2 2 0 3 70% pos. neg. 1+ 16.6/17.1 15.8/16.3 14.2/14.5 invasive ductal
3 2 1a 2 70% pos. pos. 1+ 17.2/17.7 16.4/16.6 14.3/14.0 mixed (duct./lob)
6 1c 3a 3 >90% pos. pos. 3+ 15.7/16.2 17.2/18.1 14.5/15.4 invasive ductal
8 2 2a 3 >90% pos. pos. 2+ 16.5/17.2 15.8/16.3 14.7/14.7 invasive ductal
10 1c N.A. 2 >90% pos. pos. 2+ 14.5/16.6 15.2/16.2 13.5/14.4 invasive ductal
13 2 3a 3 >90% pos. neg. 1+ 16.6/17.0 15.7/15.6 14.6/14.5 invasive ductal
14 1c N.A. 2 >90% pos. neg. 1+ 16.5/16.9 16.2/16.4 13.8/13.5 invasive ductal
15 N.A. 3 neg. neg. 0 11.8/13.0 14.9/15.5 14.9/15.5 invasive ductal
16 2 N.A. 1 65% pos. pos. 0 17.9/18.3 16.4/16.6 13.8/14.1 invasive ductal/cribriform
17 2 0 3 >90% pos. pos. 2+ 16.5/17.2 16.3/16.9 14.9/15.6 invasive ductal
18 2 N.A. 3 neg. neg. 0 13.0/12.9 15.1/15.9 15.2/16.0 invasive ductal
19 2 N.A. 2 >90% pos. pos. 0 17.2/17.6 15.9/16.0 13.8/14.2 invasive ductal
20 1c N.A. 2 neg. neg. 0 12.4/13.0 15.7/15.9 14.6/15.2 invasive ductal
22 2 0 2 N.A. N.A. N.A. 16.8/17.4 15.6/16.1 13.3/13.9 invasive ductalPage 10 of 15
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Comparison of Total scores computed from intact and FFPE-derived RNAFigure 7
Comparison of Total scores computed from intact and FFPE-derived RNA. Total scores were computed from nor-
malized expression values based on the results of intact RNA ( ) and FFPE-derived RNA (, own protocol) as described in the 
Methods section. They are shown separately for each of the 14 tumors.
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Module scoresFigur 8
Module scores. ER, HER2 and proliferation scores were computed from expression values of 14 breast cancers and visual-
ized in a scatter plot. The ER score was determined from four genes, the HER2 score from 2 and the proliferation score from 
5 genes (see Methods). Tumors are positioned according to their ER score (x-axis) and HER2 score (y-axis). Proliferation 
scores are color coded. The histological ER status is indicated by a "-" or "+" sign next to the tumor numbers in the plot. The 
results were computed from intact RNA derived of FF material (A) and RNA isolated from FFPE material according to our 
own protocol (B). Individual scores for each tumor are given in Table 2.
BMC Medical Genomics 2008, 1:9 http://www.biomedcentral.com/1755-8794/1/9ence gene has a stable expression level in all the samples
under investigation. As such "ideal" reference gene nor-
mally does not exist, the mean or median expression level
of several suitably chosen reference genes is used as a rel-
atively stable reference Ct value. We used a formalized
approach to characterize all candidate reference genes.
Candidate reference genes were ranked according to their
standard deviations of raw Ct values in RNA from FF and
FFPE material. The final rank of each candidate reference
gene was taken as the mean of the two ranks obtained
with RNA from intact and FFPE material. Genes with
higher ranks were excluded as reference genes.
We also applied GeNorm [14] to characterize candidate
reference genes: ACTB and RPS11 had poorest stability
measure M [14] for FFPE-derived RNA and RPL7A had a
poor stability measure when RNA from FF material was
tested (data not shown). For these reasons GAPDH,
GUSB, RPLP0, TFRC and UBB were used as reference
genes in this study.
Our own RNA isolation protocol was compared to RNA
that was isolated from the same material but according to
commercial protocols and products (Qiagen RNeasy FFPE
and ncLysis system of Applied Biosystems). Additional
products for FFPE material from commercial providers
(e.g. Stratagene, Ambion) were tested and the results
obtained with our own protocol were superior to all tested
commercial products (data not shown).
We determined module scores for each of the 14 tumors
in this study. The limited number of samples does not
allow statements about the clinical significance of module
scores but they can be used to compare scores computed
from intact RNA from FF material and RNA isolated from
FFPE according to our own protocol. Pearson correlations
between these RNAs in the 14 tumors were 0.966, 0.856
and 0.833 for ER, HER2 and Proliferation scores, respec-
tively. As kryo-preserved RNA and RNA from FFPE mate-
rial always originated from different portions of the same
tumor, a certain variation of gene expression cannot be
excluded and, as a consequence, part of the observed var-
iability between kryo and FFPE material may be attributed
to biological heterogeneity in the tumors. The three mod-
ule scores were combined to a Total score. The Total score
is similar to the recurrence score described by Paik [11],
with high expression of genes related to proliferation and
HER2 and low expression of ER-related genes indicating
higher risk.
The data generated from FF and FFPE material were also
compared to ER and HER2 levels assessed by IHC results
from the same tumors. Three tumors (#15, #18, #20) were
ER-negative and one was strongly HER2-positive (#6)
(Tab. 2). The same tumors had low ER scores when
assessed by QPCR (Fig. 8). Tumor #6 had a high HER2
score and an intermediate ER score. These results are in
good agreement with the expected distribution of the
three scores [15,39]. By comparing QPCR based data with
well known tumor subtypes allowed to validate the proto-
cols developed here, even if no new biological findings are
provided. The primary issue of this work was to document
that stable and robust expression values can be deter-
mined from FFPE-derived RNA which are close to the val-
ues computed from intact RNA of the same tumors. The
optimization and validation of the scoring procedure
remains an important issue but obviously, the available
number of samples is not sufficient to deal with this
aspect and it will be addressed separately and on a larger
collection of samples.
While IHC results are at most semi-quantitative, QPCR-
based results reflect more accurately the expression level
of genes in question. The module scores proposed here
integrate quantitative gene expression data from several
genes, this makes the resulting scores more robust than
measurements based on single genes. QPCR is not only
quantitative, it is also very sensitive over a large dynamic
range. The number of genes which can be measured by
QPCR is not limited and additional genes and module
scores can be included in the analysis if this will be
required.
Importantly, certain predictive parameters still cannot be
determined with current technologies. For example,
breast cancers are classified into histological grade 1, 2 or
3. This grading most likely reflects the proliferative state of
tumor cells [40]. Grading may be especially important as
high grade tumors seem to respond more favorably to
chemotherapy than low grade tumors. Unfortunately,
many tumors are histological grade 2 and for those
tumors the benefit is not clear. Paik and co-workers docu-
mented that their recurrence score (RS) was also predic-
tive for a response to chemotherapy [41]. The RS defined
by Paik and coworkers is composed of 16 test genes
mainly representing ER response genes, proliferation-
associated genes, HER2-related genes and invasion genes
and 5 genes for normalization [11,41].
The genes selected for this study (Tab. 1) were selected
from published DNA chip studies with breast cancer sam-
ples [15]. They mostly coincide with the genes used by
Paik ad co-workers.
Conclusion
The results presented in this study reveal that RNA iso-
lated from FFPE material according to the protocol devel-
oped in our laboratory can be used for expression
measurements by QPCR although the RNA is partially
degraded. The optimized isolation and de-modificationPage 13 of 15
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results in stable and robust gene expression data. Robust-
ness of results was further increased by computing scores
from several genes representing the hormonal and the
proliferation status of the tumor. Molecular profiling
from FFPE material may be of interest for routine diagnos-
tics in the near future as FFPE material is always available
[42]. Similarly, molecular profiling from FFPE material
may be of great interest in the context of existing and
newly planed clinical trials for which only formalin-fixed
samples exist.
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